These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26333301)

  • 1. Low-cost oral delivery of protein drugs bioencapsulated in plant cells.
    Kwon KC; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1017-22. PubMed ID: 26333301
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-frequency enzyme replacement therapy in late-onset Pompe disease.
    Lin DS; Chiang MF; Ho CS; Hsiao CD; Lin CY; Wang NL; Chuang CK; Huang YW; Chang PC; Liu HL
    Muscle Nerve; 2013 Apr; 47(4):612-3. PubMed ID: 23322609
    [No Abstract]   [Full Text] [Related]  

  • 5. First treatment for Pompe disease.
    FDA Consum; 2006; 40(4):3. PubMed ID: 17245826
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA balks at Myozyme scale-up.
    Mack G
    Nat Biotechnol; 2008 Jun; 26(6):592. PubMed ID: 18536660
    [No Abstract]   [Full Text] [Related]  

  • 7. Ptosis in Pompe disease: common genetic background in infantile and adult series.
    Ravaglia S; Bini P; Garaghani KS; Danesino C
    J Neuroophthalmol; 2010 Dec; 30(4):389-90. PubMed ID: 21107130
    [No Abstract]   [Full Text] [Related]  

  • 8. Alglucosidase alfa and Pompe disease: still going strong?
    Lipinski SE
    Mol Genet Metab; 2012 Nov; 107(3):245-6. PubMed ID: 23034445
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
    Spiridigliozzi GA; Heller JH; Kishnani PS; Van der Ploeg AT; Ebbink BJ; Aarsen FK; van Gelder CM; Van den Hout JM
    Neurology; 2013 Mar; 80(12):1173. PubMed ID: 23509050
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune modulation in Pompe disease treated with enzyme replacement therapy.
    Banugaria SG; Patel TT; Kishnani PS
    Expert Rev Clin Immunol; 2012 Aug; 8(6):497-9. PubMed ID: 22992140
    [No Abstract]   [Full Text] [Related]  

  • 11. Desensitisation of the youngest patient with Pompe disease in response to alglucosidase alfa.
    Karagol IH; Bakirtas A; Yilmaz O; Topal E; Kucukcongar A; Ezgu FS; Demirsoy MS; Turktas I
    Allergol Immunopathol (Madr); 2014; 42(4):372-5. PubMed ID: 23769736
    [No Abstract]   [Full Text] [Related]  

  • 12. Enzyme replacement for infantile Pompe disease: the first step toward a cure.
    Wagner KR
    Neurology; 2007 Jan; 68(2):88-9. PubMed ID: 17210887
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pompe's disease].
    Laforêt P
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S290-1. PubMed ID: 18029059
    [No Abstract]   [Full Text] [Related]  

  • 14. Pompe disease therapy presents coverage challenge.
    Morrow T
    Manag Care; 2006 Jun; 15(6):63-4. PubMed ID: 16838889
    [No Abstract]   [Full Text] [Related]  

  • 15. alpha-glucosidase (CHO) (Genzyme).
    Lachmann RH
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1101-10. PubMed ID: 15535432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pompe disease in infants and children.
    Kishnani PS; Howell RR
    J Pediatr; 2004 May; 144(5 Suppl):S35-43. PubMed ID: 15126982
    [No Abstract]   [Full Text] [Related]  

  • 17. From symptoms to causes: progress in the treatment of neurological disease.
    Sells RA; Larner AJ
    Br J Hosp Med (Lond); 2011 Jun; 72(6):350-1. PubMed ID: 21727816
    [No Abstract]   [Full Text] [Related]  

  • 18. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease.
    Yanovitch TL; Casey R; Banugaria SG; Kishnani PS
    J Neuroophthalmol; 2010 Jun; 30(2):165-6. PubMed ID: 20404746
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA approves new treatment for late-onset Pompe disease.
    Home Healthc Nurse; 2010 Sep; 28(8):457. PubMed ID: 20811179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.